Indomethacin, Troxerutin

Pharmacological properties

Indovazinum is a combined therapeutic agent, which includes indomethacin and troxerutin. indomethacin has a pronounced anti-inflammatory, analgesic and decongestant effect. its use leads to the elimination of pain, reduction of edema and a reduction in the time of functional rehabilitation in case of damage to joints and tissues. the mechanism of action is associated with inhibition of prostaglandin synthesis by reversible blockade of cog. indomethacin has a more pronounced anti-inflammatory effect compared with salicylates and phenylbutazone.

Troxerutin (trihydroxyethylrutinoside) is a bioflavonoid. It belongs to angioprotective agents. Troxerutin reduces capillary permeability and exhibits a venotonic effect. It blocks the venodilating effect of histamine, bradykinin and acetylcholine. It has an anti-inflammatory effect on the circulatory tissue, reduces capillary fragility and exhibits a certain antiaggregant effect. Reduces edema, improves trophism in pathological changes that are associated with venous insufficiency.

When applied to the skin, Indovazin inhibits the reactions of inflammation and edema, eliminates pain and temperature in the foci of inflammation (outside and in the deep tissues, reaching the blood vessels). It exhibits venotonic, capillaroprotective and hemostatic effects.

The gel base of the drug contributes to the complete solubility of the active substances and their maximum release. Dosage form in the form of a gel, which included indomethacin and troxerutin, provides good absorption from the surface of the skin and therapeutic effect at different levels, creating the necessary concentration in inflamed tissues and synovial fluid.

Indomethacin binds to plasma proteins by more than 90% and lends itself to intensive biotransformation in the liver by O-demethylation and N-deacetylation to inactive compounds.

Troxerutin is a mixture of hydroxyethyl derivatives of rutin bioflavonoid (O- (B-hydroxyethyl) rutosides), in which trihydroxyethyl rutoside (troxerutin) predominates.

Indomethacin is excreted in urine (60%), bile and feces (30%). It penetrates into breast milk, and therefore the use of indovazine during breast-feeding is not recommended.

Most of the resorbed tri-, di- and monohydroxyethylrutosides are excreted in the bile, a much smaller part - by the kidneys. Tetrahydroxyethylrutoside is excreted mainly in urine.

Indications

Bruises, sprains, dislocations, bruises, edema, myositis, neuralgia, lumbago, sciatica, radiculitis, osteochondrosis, arthritis, joint pain.

Application

It is applied externally: 4–5 cm of the gel is applied 3-4 times a day with a thin layer on the affected areas with light massaging movements. the total daily dose should not exceed 20 cm. The duration of treatment is no more than 10 days.

Contraindications

Hypersensitivity to the components of the drug; hypersensitivity to NSAIDs.

Side effects

In single cases, there are reactions of skin irritation in the form of hyperemia, itching, skin rashes, which quickly pass after discontinuation of the drug.

special instructions

Indomethacin is not recommended for children under 14 years of age due to the lack of sufficient clinical experience.

It is not recommended to prescribe the drug to patients with a history or proven hypersensitivity to food and medicine; in the presence of AD, allergic rhinitis or other allergies.

Indovazin is applied only to intact skin. It is necessary to avoid getting the gel on the mucous membranes, open surfaces of wounds and eyes.

With a treatment duration of more than 10 days, laboratory monitoring of the leukocyte and platelet blood counts is necessary.

The product contains sodium benzoate and propylene glycol, which can cause skin irritation.

Given that there is no clinical experience that proves the safety of Indovazin during pregnancy and lactation, the use of the drug is possible only in cases where the benefits of its use prevail over the potential risk.

Interactions

The drug should not be used together with other NSAIDs (potentiation of the effect) and corticosteroids (possible potentiation of their ulcerogenic effect).

Overdose

No cases of overdose have been reported with topical administration of the drug.

With prolonged treatment (more than 10 days), the manifestation of systemic effects is possible - hepatotoxicity, severe headache, hemorrhage. Monitoring of leukocyte and platelet blood counts is necessary.

In case of accidental swallowing of Indovazin, a burning sensation in the oral cavity, salivation, nausea, and vomiting are possible. In such cases, it is necessary to rinse the oral cavity and stomach, and if necessary, carry out symptomatic treatment.

In case of contact with eyes, mucous membranes and open wounds, local irritation is observed - lacrimation, redness, burning, pain. Necessary measures to eliminate the consequences - washing the areas of the accidental ingestion of the drug with a large amount of distilled water or saline until the disappearance or reduction of these symptoms.

Storage conditions

In a dry place in tightly closed original packaging at temperatures up to 25 ° C.